Related Experiment Video
Updated: Oct 14, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.2K
Medication Adherence in Indian Epilepsy Patients.
Shrawan Kumar1, Mamta Bhushan Singh1, Amit Kumar1
1Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Annals of Indian Academy of Neurology
|November 3, 2021
Summary
Approximately 30% of epilepsy patients exhibit poor adherence to antiepileptic drugs (AEDs). Factors like polytherapy, adverse events, and long treatment duration significantly increase non-adherence risks.
Area of Science:
- Neurology
- Pharmacology
- Public Health
Background:
- Medication adherence is crucial for epilepsy management and patient quality of life.
- Poor adherence to antiepileptic drugs (AEDs) hinders sustained remission and functional recovery in a significant patient population.
Purpose of the Study:
- To determine the prevalence of antiepileptic drug (AED) non-adherence among adult epilepsy patients.
- To identify key factors associated with AED non-adherence in this population.
Main Methods:
- Subgroup analysis of a single-center, cross-sectional study including adult patients (≥18 years).
- Adherence assessed using the 4-item Morisky Medication Adherence Scale.
- Multivariable logistic regression employed to identify predictors of AED non-adherence.
Main Results:
- Out of 268 participants, 81 (30%) demonstrated non-adherence to AEDs.
- AED polytherapy (OR: 4.5) was strongly associated with non-adherence.
- Drug-related adverse events (OR: 3.9) and treatment duration exceeding 3 years (OR: 2.6) were also significant predictors.
Conclusions:
- Nearly one-third of epilepsy patients struggle with medication compliance.
- Strategies to reduce non-adherence include prioritizing AED monotherapy and educating patients on treatment duration and potential adverse effects.
More Related Videos
Related Concept Videos
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.1K
01:28Drug Therapy
118
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
118
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
519
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
519
01:20Antiepileptic Drugs: Potassium Channel Activators
351
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
351
01:14Antiepileptic Drugs: Glutamate Antagonists
590
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
590
01:17Antiepileptic Drugs: Calcium Channel Blockers
746
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
746